Paclitaxel-ifosfamide for anthracycline-resistant advanced breast cancer

Area of Science:

• Oncology
• Medical Research
• Pharmacology

Background:

• Advanced breast cancer often develops resistance to standard anthracycline-based chemotherapy.
• Patients relapsing after adjuvant anthracycline treatment require alternative therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy and safety of a combination regimen of paclitaxel and ifosfamide in advanced breast cancer patients.
• To assess response rates, survival outcomes, and toxicity profiles in a heavily pretreated patient population.

Main Methods:

• A phase II study involving 31 patients with advanced breast cancer resistant or relapsed to anthracyclines.
• Treatment consisted of paclitaxel (135 mg/m2) followed by ifosfamide (1.7 g/m2) over 22-day cycles.
• Response and toxicity were assessed using World Health Organization (WHO) and National Cancer Institute (NCI) criteria, respectively.

Main Results:

• An overall response rate of 42% was observed, including 13% complete responses.
• Median progression-free survival was 6.1 months, and median overall survival was 19.3 months.
• Grade 3-4 neutropenia occurred in 88% of patients, but severe non-hematological toxicity was less than 8%.

Conclusions:

• The combination of paclitaxel and ifosfamide demonstrates promising efficacy in advanced breast cancer patients with anthracycline resistance or relapse.
• This regimen offers a viable treatment option with an acceptable toxicity profile for this patient group.
• Further investigation into this combination therapy for advanced breast cancer is warranted.